# South Korea Fibroscan Market > South Korea FibroScan Market Research Report By Technology (Vibration-controlled Transient Electrography (VCTE), Controlled Attenuation Parameter (CAP), Others), By Modality (Portable, Non-Portable/Standalone), By Application (Hepatitis B or C, Nonalcoholic Fatty Liver Disease, Alcohol-related Liver Problems, Hemochromatosis, Others) and By End-user (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.0% - **2024:** $ 1,956 Million - **2025:** $ 2,053.8 Million - **2035:** $ 3,347 Million - **Key Players:** Echosens (FR), FibroScan (FR), Siemens Healthineers (DE), GE Healthcare (US), Philips Healthcare (NL), Medtronic (US), Canon Medical Systems (JP), Hitachi Medical Corporation (JP) **Report ID:** MRFR/HC/50529-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-fibroscan-market-52287 --- ## Market Summary ## **South Korea FibroScan Market Overview** As per MRFR analysis, the South Korea FibroScan Market Size was estimated at 1.86 (USD Billion) in 2024.The South Korea FibroScan Market Industry is expected to grow from 2(USD Billion) in 2025 to 4 (USD Billion) by 2035. The South Korea FibroScan Market CAGR (growth rate) is expected to be around 6.504% during the forecast period (2025 - 2035) **Key South Korea FibroScan Market Trends Highlighted** The South Korea FibroScan Market is experiencing significant growth driven by an increasing prevalence of liver diseases, such as fatty liver and hepatitis, largely due to lifestyle changes and aging population. The government’s initiatives to improve public health awareness and the promotion of early diagnosis of liver diseases are propelling the demand for non-invasive diagnostic technologies like FibroScan. There is a heightened emphasis on routine screening, particularly in at-risk populations, reflecting a shift in healthcare policy towards preventative care.  Recent trends indicate a growing adoption of advanced FibroScan devices in hospitals and outpatient clinics, fueled by technological advancements that enhance accuracy and user-friendliness.Healthcare providers are increasingly favoring FibroScan over traditional biopsy methods, which are invasive and carry risks. Furthermore, as South Korea's healthcare system evolves, the integration of telemedicine is becoming prominent, enabling remote consultations and monitoring, which complements the use of FibroScan technology.  Opportunities to be explored in this market include the expansion of FibroScan services outside major urban centers, reaching rural areas where liver diseases are often underdiagnosed. The collaboration between healthcare facilities and technology providers will enhance product offerings and capabilities. There is also potential for research and development aimed at tailoring FibroScan applications for specific demographics, particularly the elderly population who are more susceptible to liver-related health issues.The ongoing emphasis on technological innovation and increased accessibility positions the South Korean FibroScan Market favorably for future growth. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea FibroScan Market Drivers** **Increasing Prevalence of Liver Diseases** The South Korea FibroScan Market Industry is witnessing significant growth driven by the increasing prevalence of liver diseases such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Hepatitis. According to the Korean Society of Gastroenterology, approximately 25% of the South Korean population is affected by fatty liver disease, a number that has been rising annually. This surge in liver-related health issues necessitates advanced diagnostic tools like FibroScan, intensifying the demand for this technology. With increasing concern about liver health and its preventative treatment, the South Korean government, along with healthcare institutions, is adopting better diagnostic tools, which have led to widespread use of FibroScan in clinics. The incorporation of these systems, FibroScan in particular, will play a key role in tracking the advancement of liver fibrosis while increasing the overall focus and requirement for liver disease diagnosis and treatment in the country. **Government Initiatives for Health Promotion** Government initiatives aimed at promoting liver health are expected to accelerate the growth of the South Korea FibroScan Market Industry. The South Korean Ministry of Health and Welfare has implemented various health promotion campaigns targeting liver disease awareness, leading to an enhanced healthcare infrastructure for early diagnosis and preventive care.  With a focus on research funding and development for liver diseases, the ministry has contributed to a significant increase in liver screening programs across the nation.The rising emphasis on early detection facilitated by such initiatives is likely to create a favorable environment for the adoption of technologies like FibroScan, reflecting the government's commitment to tackling liver health issues effectively. **Technological Advancements in FibroScan Devices** The advancement in medical technologies is another key driver for the South Korea FibroScan Market Industry. The continuous innovation in non-invasive liver assessment devices, such as FibroScan, is enabling healthcare professionals to obtain precise measurements of liver stiffness and fat content efficiently. With major manufacturers investing heavily in Research and Development, the availability of upgraded and user-friendly FibroScan models is increasing.As the medical device companies enhance their products' accuracy and reliability, more hospitals and clinics in South Korea are likely to adopt these technologies.  Furthermore, collaborations between medical technology firms and healthcare institutions have the potential to drive the widespread implementation of these devices in clinical practice, thereby facilitating better liver disease management and monitoring within the region. **South Korea FibroScan Market Segment Insights** **FibroScan Market Technology Insights** The South Korea FibroScan Market is witnessing a robust growth trajectory, particularly in the Technology segment, which is vital for advancing liver health diagnosis techniques. The Vibration-controlled Transient Electrography (VCTE) technology has garnered significant attention due to its non-invasive capabilities, enabling accurate measurement of liver stiffness. This feature is essential as liver fibrosis affects a considerable portion of the population in South Korea, necessitating effective monitoring and management strategies.  Furthermore, the Controlled Attenuation Parameter (CAP) technology plays a pivotal role in determining steatosis levels, which further aids in managing conditions like Non-Alcoholic Fatty Liver Disease (NAFLD), a growing concern among the Korean population.The ability of CAP to offer reliable results enhances its importance in the clinical landscape, driving its adoption among healthcare providers. In addition to these two technologies, other emerging technologies within the South Korea FibroScan Market are increasingly contributing to innovative approaches in liver disease assessment and management, leading to improved patient outcomes.  The demand for such technologies is amplified by the increasing prevalence of liver-related ailments, encouraging healthcare stakeholders to prioritize advanced diagnostic tools.The overall South Korea FibroScan Market revenue reflects the expanding awareness and the pressing need for effective tools in early liver disease detection, as improved technological solutions become more integral in fostering better health care delivery. Furthermore, government initiatives focusing on health technology advancements and patient care optimization promote a conducive environment for the growth of advanced offerings in this sector.  As a result, the South Korea FibroScan Market segmentation based on technology not only showcases the rise of VCTE and CAP but also emphasizes the entire industry's potential for innovation and improvement in healthcare practices in the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **FibroScan Market Modality Insights** The Modality segment within the South Korea FibroScan Market showcases a diverse landscape, primarily divided into Portable and Non-Portable/Standalone categories. The Portable FibroScan devices are gaining traction due to their versatility and convenience, facilitating point-of-care testing that proves critical in rural or underserved areas. This aligns with South Korea's goal of enhancing healthcare accessibility and early detection of liver diseases among its population.  On the other hand, Non-Portable/Standalone devices tend to dominate in clinical settings, where advanced features and comprehensive data analysis are essential for accurate diagnosis and monitoring of liver health.The combination of these modalities supports a significant shift toward non-invasive assessment methods, which are less traumatic for patients and yield reliable results. Furthermore, the growing awareness of liver health issues, along with the increasing prevalence of hepatitis and fatty liver diseases, drives the demand for both these categories.  As healthcare providers in South Korea continue to prioritize innovative technologies, understanding the nuances within the Modality segment remains vital for optimizing patient outcomes and resource allocation. **FibroScan Market Application Insights** The South Korea FibroScan Market focuses on several critical applications, including Hepatitis B or C, Nonalcoholic Fatty Liver Disease, Alcohol-related Liver Problems, and Hemochromatosis among others. Hepatitis B and C remain significant public health concerns in South Korea, with a considerable number of individuals affected, driving the demand for advanced diagnostic tools such as FibroScan to assess liver conditions effectively. Nonalcoholic Fatty Liver Disease is increasingly prevalent due to lifestyle changes and rising obesity rates, making it an important area of focus for liver health management.Alcohol-related liver problems continue to pose serious health risks, necessitating regular monitoring and timely intervention through FibroScan technologies.  Hemochromatosis, a hereditary condition leading to excessive iron accumulation, also emphasizes the need for precise liver evaluation techniques. As these conditions dominate the landscape of liver diseases in South Korea, the overall significance of the respective applications underlines the growing focus on early diagnosis and management. The South Korea FibroScan Market segmentation shows potential growth opportunities fueled by increasing awareness and healthcare investments in liver health. **FibroScan Market End-user Insights** The End-user segment of the South Korea FibroScan Market encompasses various essential healthcare providers crucial for advancing liver health diagnostics. Hospitals and clinics stand out due to their extensive reach and integrated care approach, facilitating early disease detection and improved patient outcomes. Diagnostic centers play a significant role, offering specialized imaging services that enhance the precision of liver fibrosis assessments. Ambulatory surgical centers are gaining traction, providing convenient outpatient procedures, which contribute to reduced patient wait times and increased efficiency. Additionally, the 'Others' category, comprising niche healthcare facilities, is becoming increasingly relevant as they address specific patient needs and contribute to the overall diversification of the market. With the rising prevalence of liver diseases in South Korea, driven by factors such as obesity and alcohol consumption, the demand for accurate and non-invasive diagnostic techniques will likely boost investments in these facilities. The increasing awareness of liver health and the need for regular monitoring underline the importance of these end-users in the South Korea FibroScan Market, highlighting their significant role in managing chronic liver conditions effectively. **South Korea FibroScan Market Key Players and Competitive Insights** The South Korea FibroScan Market is characterized by a competitive landscape that focuses on advanced diagnostic technologies aimed at liver health assessments. FibroScan, a non-invasive method for measuring liver stiffness and fat content, has gained considerable traction in South Korea, largely driven by an increasing prevalence of liver diseases, including non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis. The demand for effective and less invasive diagnostic tools is pushing establishments in this market to adapt and innovate further. Competitors are vying for market share through extensive research and development efforts, strategic partnerships, and tailored marketing strategies to cater to healthcare providers and patients' needs.  With a rising emphasis on preventative healthcare and early diagnosis, the competition among firms has intensified, making it essential for companies to enhance their product offerings to seize market opportunities.Fujifilm Holdings Corporation holds a prominent position in the South Korea FibroScan Market with its advanced imaging technology and strong brand reputation. The company leverages its cutting-edge solutions in diagnostics, particularly in liver health monitoring, to enhance patient care. With the ability to provide high-quality diagnostic imaging, Fujifilm has established itself as a leader, catering to the increasing demand for reliable liver disease diagnosis in South Korea.  The strengths of Fujifilm include its commitment to innovation, significant investment in research and development, and strategic collaborations within the healthcare sector, all of which solidify its presence in the market. This allows Fujifilm to not only meet current healthcare needs but also to anticipate future demands as the market evolves.Biosense Webster operates in the South Korea FibroScan Market with a focus on developing and delivering advanced therapeutic solutions that complement their diagnostic technologies. Known for their innovative healthcare products, Biosense Webster has carved a niche in the field by providing robust diagnostic tools that cater specifically to healthcare providers in South Korea.  The company’s strengths lie in its ability to create high-quality products aimed at improving patient outcomes, as well as its dedication to expanding its market presence through strategic partnerships and mergers and acquisitions that enhance its product portfolio. Biosense Webster continuously seeks to innovate and expand its offerings, focusing on integrating more advanced diagnostic features suited for liver health assessments, which reinforces its competitive edge in the South Korean market. Their ongoing commitment to research and development positions them favorably amidst evolving healthcare demands, enabling them to better serve medical professionals and patients alike. **Key Companies in the South Korea FibroScan Market Include** **South Korea FibroScan Market Industry Developments** Recent developments in the South Korea FibroScan Market have been marked by growth and technological advancements from key players like Fujifilm Holdings Corporation, Siemens Healthineers, and GE Healthcare. In October 2023, GE Healthcare announced the launch of a new FibroScan device aimed at enhancing liver disease diagnosis, leveraging cutting-edge technology to improve patient outcomes. Additionally, Echosens has been expanding its market reach by enhancing collaborations with local healthcare institutions to improve non-invasive liver diagnostics. In terms of market valuation, the South Korean FibroScan sector has seen a steady increase, attributed to rising incidences of liver-related diseases and a growing awareness of non-invasive diagnostic methods. Over the past two years, significant partnerships have emerged, including Canon Medical Systems Corporation's collaboration with local hospitals to conduct extensive clinical trials for advanced liver imaging technologies in June 2022. Notably, reports suggest that Siemens Healthineers is evaluating strategic acquisition opportunities in the region to bolster its portfolio. The South Korean government's support for innovative healthcare solutions further fuels the positive trajectory of the FibroScan market, fostering an environment conducive to growth and innovation within the healthcare sector. **South Korea FibroScan Market Segmentation Insights** ## Market Drivers ### Growing Geriatric Population The demographic shift towards an aging population in South Korea is a notable driver for the fibroscan market. As the elderly population continues to expand, the prevalence of age-related health issues, including liver diseases, is expected to rise. Older adults are more susceptible to conditions such as cirrhosis and liver cancer, necessitating regular monitoring and assessment of liver health. Fibroscan technology, with its non-invasive approach, is particularly appealing for this demographic, as it minimizes discomfort and risk associated with traditional biopsy methods. Therefore, the increasing geriatric population is likely to contribute to the heightened demand for fibroscan devices, thereby propelling the growth of the fibroscan market. ### Advancements in Medical Technology Technological innovations in medical devices are playing a pivotal role in shaping the fibroscan market. Recent advancements have led to the development of more sophisticated and user-friendly fibroscan devices, enhancing their accuracy and efficiency. These improvements not only facilitate better diagnosis but also increase the accessibility of fibroscan technology in various healthcare settings, including outpatient clinics and hospitals. The integration of artificial intelligence and machine learning into fibroscan devices is expected to further refine diagnostic capabilities. As a result, the enhanced performance and reliability of these devices are likely to attract more healthcare providers, thereby stimulating growth in the fibroscan market. ### Government Initiatives for Liver Health The South Korean government has been actively promoting initiatives aimed at improving liver health, which serves as a significant driver for the fibroscan market. Various public health campaigns and educational programs are being implemented to raise awareness about liver diseases and the importance of early detection. Additionally, the government is investing in healthcare infrastructure, which includes the procurement of advanced diagnostic tools like fibroscan devices. These initiatives not only enhance public access to liver health screenings but also encourage healthcare facilities to adopt innovative technologies. Consequently, the supportive regulatory environment is likely to foster growth in the fibroscan market. ### Increasing Prevalence of Liver Diseases The rising incidence of liver diseases in South Korea is a crucial driver for the fibroscan market. Conditions such as non-alcoholic fatty liver disease (NAFLD) and hepatitis are becoming more common, affecting a significant portion of the population. According to recent health statistics, approximately 25% of adults in South Korea are estimated to have some form of liver disease. This alarming trend necessitates the need for effective diagnostic tools, such as fibroscan devices, which provide non-invasive assessments of liver stiffness and fat content. As healthcare providers seek to improve patient outcomes, the demand for fibroscan technology is likely to increase, thereby propelling the growth of the fibroscan market in the region. ### Rising Awareness of Preventive Healthcare There is a growing awareness among the South Korean population regarding the importance of preventive healthcare, which significantly impacts the fibroscan market. As individuals become more health-conscious, they are increasingly seeking early detection methods for potential health issues, particularly liver-related conditions. This shift in mindset is reflected in the increasing number of health check-ups and screenings being conducted across the country. The fibroscan technology, known for its non-invasive nature and quick results, aligns well with this trend. Consequently, healthcare providers are likely to incorporate fibroscan devices into routine examinations, further driving the demand for these diagnostic tools in the fibroscan market. ## Future Outlook The [Fibroscan Market](https://www.marketresearchfuture.com/reports/fibroscan-market-21914) in South Korea is projected to grow at a 5.0% CAGR from 2025 to 2035, driven by technological advancements and increasing liver disease prevalence. **New opportunities:** - Development of portable fibroscan devices for remote diagnostics - Partnerships with healthcare providers for integrated screening programs - Expansion into emerging markets with tailored pricing strategies By 2035, the fibroscan market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Technology: Vibration-controlled transient electrography (VCTE) (Largest) vs. Controlled Attenuation Parameter (CAP) (Fastest-Growing) In the South Korea fibroscan market, Vibration-controlled transient electrography (VCTE) accounts for a significant share, establishing itself as the largest segment among the technologies used. Its advanced methodology and high accuracy in measuring liver stiffness have positioned it as the preferred choice for healthcare providers. In contrast, Controlled Attenuation Parameter (CAP) is rapidly gaining traction, although it holds a smaller market share. This segment is essential for assessing liver steatosis as it complements the capabilities of VCTE. Technology: VCTE (Dominant) vs. CAP (Emerging) Vibration-controlled transient electrography (VCTE) stands out as the dominant technology within the South Korea fibroscan market due to its superior accuracy and reliability, allowing detailed insights into liver conditions. VCTE is widely recognized for its non-invasive approach, making it highly appealing for clinical settings. On the other hand, Controlled Attenuation Parameter (CAP), while still emerging, offers unique advantages by providing specific data on hepatic fat content. Its integration with existing VCTE technology enhances diagnostic capabilities, making it a valuable asset in clinical environments. The rise of CAP reflects growing awareness of liver health issues and a shift towards comprehensive liver assessments. ### By Modality: Portable (Largest) vs. Non-Portable/Standalone (Fastest-Growing) The South Korea fibroscan market exhibits a significant divide in modality preferences, with the portable segment commanding a larger share of the market. This modality allows for greater accessibility and flexibility, making it a preferred choice among healthcare providers who need to perform assessments in various settings. Meanwhile, the non-portable or standalone segment is rapidly gaining traction as advancements enhance its capabilities, attracting hospitals and clinics focused on high-accuracy diagnostics. Growth trends in the modality segment reveal a dynamic shift towards portable solutions driven by the increasing need for point-of-care testing. The convenience of portable devices is fueling their adoption in remote and rural areas, while technological enhancements in non-portable systems cater to specialized clinical environments. As a result, these two segments are expected to evolve, with portable retaining its dominant position while non-portable emerges as a significant force. Modality: Portable (Dominant) vs. Non-Portable/Standalone (Emerging) The portable modality stands as the dominant choice in the South Korea fibroscan market, characterized by its user-friendly design and ability to provide on-the-spot diagnostics. This modality caters to a wide range of healthcare settings, delivering results quickly and efficiently, thus enhancing patient experiences. Conversely, the non-portable or standalone modality is emerging with robust technology aimed at improving diagnostic accuracy and enabling comprehensive assessments. While this segment may lack the flexibility of portable options, its strength lies in detailed analysis capabilities, making it indispensable in specialized environments where precision is paramount. Both segments are significant, catering to different clinical needs, and their interplay will shape the future landscape. ### By Application: Hepatitis B or C (Largest) vs. Nonalcoholic fatty liver disease (Fastest-Growing) In the South Korea fibroscan market, the application segment is primarily dominated by Hepatitis B or C, representing the largest share due to the high prevalence of these conditions within the population. This segment has become essential for the diagnosis and monitoring of liver health, owing to the increasing awareness and advancements in fibroscan technology. Other applications such as Nonalcoholic fatty liver disease, Alcohol-related liver problems, and Hemochromatosis follow, each contributing to the overall market but to a lesser extent. The growth trends in this segment are driven by rising incidences of liver diseases, particularly Nonalcoholic fatty liver disease, which is witnessing a surge in cases attributed to lifestyle changes. The South Korea fibroscan market is also influenced by government initiatives and improved healthcare infrastructure, leading to better accessibility of fibroscan diagnostics. As awareness grows, particularly for alcohol-related liver problems, we can expect increased adoption rates for fibroscan technology across various applications. Hepatitis B or C (Dominant) vs. Nonalcoholic fatty liver disease (Emerging) Hepatitis B or C remains the dominant application in the South Korea fibroscan market, characterized by significant screening needs and treatment management, reflecting a pressing public health concern. This segment benefits from established protocols and recognition within clinical settings as essential for liver health monitoring. In contrast, Nonalcoholic fatty liver disease is an emerging application, gaining attention as cases rise alongside dietary and health trends. As obesity levels increase, this segment is rapidly gaining ground, driven by heightened public awareness and demand for preventative health measures. Both segments showcase the importance of effective liver diagnostics, albeit positioned differently in terms of market maturity and growth potential. ### By End-User: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing) The South Korea fibroscan market exhibits a diverse distribution across various end-user segments, with Hospitals & Clinics holding the largest market share. This segment benefits from advanced healthcare infrastructure and increasing adoption of fibroscan technology for non-invasive liver assessments. Diagnostic Centers follow as significant contributors, addressing the rising demand for specialized diagnostic services and accessibility. Growth trends indicate that the Diagnostic Centers segment is emerging as the fastest-growing area within the market. This growth is primarily driven by technological advancements and increased public awareness regarding liver health. Additionally, the expanding network of healthcare facilities is facilitating higher patient footfalls in outpatient settings, further bolstering the demand for fibroscan solutions. Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging) Hospitals & Clinics represent the dominant segment in the South Korea fibroscan market due to their extensive integration of advanced diagnostic tools and emphasis on patient care quality. This segment sees substantial investment in medical technology, ensuring high standards in liver disease diagnosis and management. On the other hand, the Diagnostic Centers segment is rapidly emerging, characterized by specialized testing services and patient-centric approaches. This segment capitalizes on the increasing trend of preventive healthcare and the preference for non-invasive procedures, attracting a growing number of patients seeking efficient diagnostic solutions. Their ability to offer timely and accurate results positions them as a pivotal player in the overall healthcare landscape. ## Competitive Benchmarking The fibroscan market exhibits a dynamic competitive landscape characterized by rapid technological advancements and a growing emphasis on non-invasive diagnostic solutions. Key players such as Echosens (FR), Siemens Healthineers (DE), and GE Healthcare (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market presence. Echosens (FR) has positioned itself as a leader in non-invasive liver diagnostics, focusing on expanding its product offerings and enhancing user experience through digital solutions. Siemens Healthineers (DE) emphasizes integrating advanced imaging technologies with artificial intelligence (AI) to improve diagnostic accuracy, while GE Healthcare (US) is concentrating on expanding its global footprint through strategic collaborations and localized manufacturing initiatives.The market structure appears moderately fragmented, with several players vying for market share. This fragmentation is influenced by the diverse needs of healthcare providers and patients, prompting companies to adopt localized manufacturing and supply chain optimization strategies. The collective influence of these key players fosters a competitive environment where innovation and operational efficiency are paramount. In September Echosens (FR) announced a strategic partnership with a leading South Korean healthcare provider to enhance the accessibility of its FibroScan technology in the region. This collaboration is expected to facilitate the integration of advanced liver diagnostics into routine clinical practice, thereby expanding Echosens' market reach and reinforcing its commitment to improving patient outcomes. In October Siemens Healthineers (DE) launched a new AI-driven software update for its imaging systems, aimed at enhancing the accuracy of liver assessments. This development underscores the company's focus on digital transformation and its intent to leverage AI to streamline workflows and improve diagnostic precision, potentially setting a new standard in the fibroscan market. In August GE Healthcare (US) unveiled a new localized manufacturing facility in South Korea, aimed at reducing production costs and improving supply chain efficiency. This strategic move not only enhances GE's operational capabilities but also aligns with the growing demand for rapid access to advanced medical technologies in the region, thereby strengthening its competitive position. As of November the fibroscan market is increasingly defined by trends such as digitalization, sustainability, and AI integration. Strategic alliances are becoming more prevalent, as companies recognize the need to collaborate to drive innovation and enhance service delivery. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, reliability in supply chains, and the ability to deliver superior patient outcomes. This shift indicates a transformative phase in the market, where companies that prioritize innovation and strategic partnerships may gain a competitive edge. ## Recent News & Developments Recent developments in the South Korea FibroScan Market have been marked by growth and technological advancements from key players like Fujifilm Holdings Corporation, Siemens Healthineers, and GE Healthcare. In October 2023, GE Healthcare announced the launch of a new FibroScan device aimed at enhancing liver disease diagnosis, leveraging cutting-edge technology to improve patient outcomes. Additionally, Echosens has been expanding its market reach by enhancing collaborations with local healthcare institutions to improve non-invasive liver diagnostics. In terms of market valuation, the South Korean FibroScan sector has seen a steady increase, attributed to rising incidences of liver-related diseases and a growing awareness of non-invasive diagnostic methods. Over the past two years, significant partnerships have emerged, including Canon Medical Systems Corporation's collaboration with local hospitals to conduct extensive clinical trials for advanced liver imaging technologies in June 2022. Notably, reports suggest that Siemens Healthineers is evaluating strategic acquisition opportunities in the region to bolster its portfolio. The South Korean government's support for innovative healthcare solutions further fuels the positive trajectory of the FibroScan market, fostering an environment conducive to growth and innovation within the healthcare sector. ## Report Scope | MARKET SIZE 2024 | 1956.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 2053.8(USD Million) | | MARKET SIZE 2035 | 3347.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.0% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Echosens (FR), FibroScan (FR), Siemens Healthineers (DE), GE Healthcare (US), Philips Healthcare (NL), Medtronic (US), Canon Medical Systems (JP), Hitachi Medical Corporation (JP) | | Segments Covered | Technology, Modality, Application, End-User | | Key Market Opportunities | Growing demand for non-invasive liver disease diagnostics drives innovation in the fibroscan market. | | Key Market Dynamics | Rising demand for non-invasive liver diagnostics drives innovation and competition in the fibroscan market. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current valuation of the fibroscan market in South Korea as of 2024?** A: The overall market valuation was $1956.0 Million in 2024. **Q: What is the projected market valuation for the fibroscan market in South Korea by 2035?** A: The projected valuation for 2035 is $3347.0 Million. **Q: What is the expected CAGR for the South Korea fibroscan market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 5.0%. **Q: Which technology segment is expected to generate the highest revenue in the South Korea fibroscan market?** A: The Vibration-controlled transient electrography (VCTE) segment is expected to generate revenue between $800.0 Million and $1400.0 Million. **Q: What are the revenue projections for the Controlled Attenuation Parameter (CAP) segment in the South Korea fibroscan market?** A: The CAP segment is projected to generate revenue between $600.0 Million and $1000.0 Million. **Q: How does the portable modality compare to the non-portable modality in terms of revenue in the South Korea fibroscan market?** A: The portable modality is expected to generate revenue between $500.0 Million and $850.0 Million, whereas the non-portable modality is projected to generate between $1456.0 Million and $2497.0 Million. **Q: What applications are driving the growth of the fibroscan market in South Korea?** A: Key applications include Hepatitis B or C, projected to generate $800.0 Million to $1400.0 Million, and Nonalcoholic fatty liver disease, expected to generate $500.0 Million to $900.0 Million. **Q: Which end-user segment is anticipated to contribute the most to the South Korea fibroscan market?** A: The Hospitals & Clinics segment is anticipated to contribute revenue between $800.0 Million and $1400.0 Million. **Q: Who are the key players in the South Korea fibroscan market?** A: Key players include Echosens, Siemens Healthineers, GE Healthcare, and Philips Healthcare. **Q: What is the potential for growth in the South Korea fibroscan market over the next decade?** A: The market appears to have strong growth potential, with a projected CAGR of 5.0% from 2025 to 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-fibroscan-market-52287*